Farther Finance Advisors, LLC

Position in EXEL — Exelixis, Inc.

CIK 1992825 SAN FRANCISCO, CA

Position in EXEL

as of Mar 31, 2026 · filed Apr 7, 2026 Compact

Position Value

$705,240

-$55,561 QoQ

Shares Held

16,443

-5.3% QoQ

Ownership

0.007%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2022

14 quarters on record

Voting authority Sole 0.ToString("F0")% Shared 0.ToString("F0")% None 100.ToString("F0")%

Healthcare · as of Mar 31, 2026

Farther Finance Advisors, LLC holds $14,686,998 across 278 Biotechnology names. EXEL ranks #7 (4.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	4,752	$2,121,958
2	REGN	Regeneron Pharmaceuticals, Inc.	1,870	$1,444,836
3	MRNA	Moderna, Inc.	20,211	$1,026,718
4	SMMT	Summit Therapeutics Inc.	50,316	$953,991
5	HALO	Halozyme Therapeutics, Inc.	13,333	$861,711
6	ARWR	Arrowhead Pharmaceuticals, Inc.	11,971	$750,581
7	EXEL	Exelixis, Inc. This page	16,443	$705,240
8	BMRN	Biomarin Pharmaceutical Inc	7,857	$443,841

14 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$705,240	16,443	-5.3%	Shares	Sole	2026-04-07
2025-12-31	$760,801	17,358	+0.3%	Shares	Sole	2026-01-23
2025-09-30	$714,448	17,299	-12.2%	Shares	Sole	2025-10-14
2025-06-30	$868,816	19,710	+266.9%	Shares	Sole	2025-07-11
2025-03-31	$198,334	5,372	+6.1%	Shares	Sole	2025-04-14
2024-12-31	$168,664	5,065	+28.6%	Shares	Sole	2025-02-10
2024-09-30	$102,243	3,940	+467.7%	Shares	Sole	2024-10-29
2024-06-30	$15,594	694	+5.3%	Shares	Sole	2024-07-31
2024-03-31	$15,638	659	+2.3%	Shares	Sole	2024-05-14
2023-12-31	$15,449	644	+736.4%	Shares	Sole	2024-02-15
2023-09-30	$1,682	77	+60.4%	Shares	Sole	2023-11-14
2023-06-30	$917	48	+380.0%	Shares	Sole	2024-05-14
2023-03-31	$194	10	0.0%	Shares	Sole	2024-05-14
2022-12-31	$160	10	—	Shares	Sole	2023-09-12
No filing history on record for this holder in this stock.